Bavarian Nordic AS 2023 AR2
The report highlights Bavarian Nordic's record financial performance in 2023, where the company more than doubled its revenue to DKK 7,062 million, driven by strong travel health sales and extraordinary demand for its smallpox/mpox vaccine. Key strategic milestones included the acquisition of a travel health portfolio from Emergent BioSolutions, expanding the company's global footprint with new manufacturing and R&D facilities. On the sustainability front, the company began reporting its Scope 3 emissions and committed to establishing a Net Zero target roadmap in 2024.
Company: Bavarian Nordic AS
Sector: Health Care
Country: Denmark
Year: 2023
Type: AR2
Pages: 136
Bavarian Nordic AS
Annual Report
The report highlights Bavarian Nordic's record financial performance in 2023, where the company more than doubled its revenue to DKK 7,062 million, driven by strong travel health sales and extraordinary demand for its smallpox/mpox vaccine. Key strategic milestones included the acquisition of a travel health portfolio from Emergent BioSolutions, expanding the company's global footprint with new manufacturing and R&D facilities. On the sustainability front, the company began reporting its Scope 3 emissions and committed to establishing a Net Zero target roadmap in 2024.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2023
Reporting Period
Jan 1, 2023 - Dec 31, 2023
Fiscal Year
2023
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Assurance
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Women on Board
Women in Management
Net Zero Target
Employees